BR112018013271A2 - composições e métodos para detectar e tratar câncer de ovário - Google Patents

composições e métodos para detectar e tratar câncer de ovário

Info

Publication number
BR112018013271A2
BR112018013271A2 BR112018013271A BR112018013271A BR112018013271A2 BR 112018013271 A2 BR112018013271 A2 BR 112018013271A2 BR 112018013271 A BR112018013271 A BR 112018013271A BR 112018013271 A BR112018013271 A BR 112018013271A BR 112018013271 A2 BR112018013271 A2 BR 112018013271A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
ovarian cancer
detecting
treating ovarian
Prior art date
Application number
BR112018013271A
Other languages
English (en)
Portuguese (pt)
Inventor
Prieur Alexandre
Original Assignee
Progastrine Et Cancers S A R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progastrine Et Cancers S A R L filed Critical Progastrine Et Cancers S A R L
Publication of BR112018013271A2 publication Critical patent/BR112018013271A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112018013271A 2015-12-31 2017-01-02 composições e métodos para detectar e tratar câncer de ovário BR112018013271A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15307192 2015-12-31
EP16305138 2016-02-05
PCT/EP2017/050033 WO2017114972A1 (en) 2015-12-31 2017-01-02 Compositions and methods for detecting and treating ovarian cancer

Publications (1)

Publication Number Publication Date
BR112018013271A2 true BR112018013271A2 (pt) 2018-12-11

Family

ID=57821943

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018013271A BR112018013271A2 (pt) 2015-12-31 2017-01-02 composições e métodos para detectar e tratar câncer de ovário

Country Status (13)

Country Link
US (1) US11760808B2 (cg-RX-API-DMAC7.html)
EP (2) EP3954999B9 (cg-RX-API-DMAC7.html)
JP (2) JP6962920B2 (cg-RX-API-DMAC7.html)
KR (2) KR102428254B1 (cg-RX-API-DMAC7.html)
CN (2) CN108780091A (cg-RX-API-DMAC7.html)
AU (2) AU2017204682B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018013271A2 (cg-RX-API-DMAC7.html)
CA (2) CA3009751A1 (cg-RX-API-DMAC7.html)
EA (1) EA037015B1 (cg-RX-API-DMAC7.html)
ES (2) ES2901602T3 (cg-RX-API-DMAC7.html)
PL (1) PL3397964T3 (cg-RX-API-DMAC7.html)
SG (1) SG11201805605TA (cg-RX-API-DMAC7.html)
WO (1) WO2017114972A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240018264A1 (en) * 2015-12-31 2024-01-18 Progastrine Et Cancers S.À R.L. Compositions and methods for detecting and treating ovarian cancer
DK3720879T3 (da) * 2017-12-05 2022-06-20 Progastrine Et Cancers S A R L Kombinationsterapi mellem anti-progastrin-antistof og immunterapi til behandling af cancer
US20200390913A1 (en) 2017-12-08 2020-12-17 Ecs-Biotracker Sàrl Radiolabeled progastrin in cancer diagnosis
TW201940881A (zh) 2018-01-26 2019-10-16 瑞士商Ecs前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
EP3759492A1 (en) 2018-02-27 2021-01-06 ECS-Progastrin SA Progastrin as a biomarker for immunotherapy
JP7687224B2 (ja) * 2022-01-25 2025-06-03 株式会社三洋物産 遊技機
JP7687223B2 (ja) * 2022-01-25 2025-06-03 株式会社三洋物産 遊技機

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化b−b10
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP2567974A3 (en) 2004-09-22 2013-05-22 Cancer Advances, Inc., Monoclonal antibodies to progastrin
US7854932B2 (en) 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
WO2008157383A1 (en) * 2007-06-15 2008-12-24 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis of ovarian cancer and lung cancer
RS57966B1 (sr) * 2009-10-16 2019-01-31 Progastrine Et Cancers S A R L Monoklonska antitela na progastrin i njihova upotreba
US8900588B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Methods for treating breast cancer
US9217032B2 (en) 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
US8900817B2 (en) 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
WO2011116954A2 (en) 2010-03-24 2011-09-29 Bioréalités S.A.S. Prophylaxis of colorectal and gastrointestinal cancer
KR101576174B1 (ko) 2010-07-26 2015-12-09 르 라보레또레 쎄르비에르 간암 요법을 위한 방법 및 조성물

Also Published As

Publication number Publication date
CA3009751A1 (en) 2017-07-06
US20190002582A1 (en) 2019-01-03
JP6962920B2 (ja) 2021-11-05
JP7279761B2 (ja) 2023-05-23
JP2019502923A (ja) 2019-01-31
AU2021250840A1 (en) 2021-11-04
AU2017204682B2 (en) 2021-07-29
CA3194356C (en) 2025-04-08
EP3954999B9 (en) 2025-03-12
EP3397964B1 (en) 2021-09-29
KR102507685B1 (ko) 2023-03-08
EP3954999A1 (en) 2022-02-16
EP3397964A1 (en) 2018-11-07
KR102428254B1 (ko) 2022-08-03
SG11201805605TA (en) 2018-07-30
EA201891529A1 (ru) 2019-01-31
EP3954999B1 (en) 2025-01-15
US11760808B2 (en) 2023-09-19
ES2901602T3 (es) 2022-03-23
AU2021250840B2 (en) 2024-06-27
CN122150588A (zh) 2026-06-05
ES3015244T3 (en) 2025-04-30
WO2017114972A1 (en) 2017-07-06
EP3954999C0 (en) 2025-01-15
KR20180105647A (ko) 2018-09-28
CN108780091A (zh) 2018-11-09
JP2022009080A (ja) 2022-01-14
KR20220100100A (ko) 2022-07-14
AU2017204682A1 (en) 2018-07-19
CA3194356A1 (en) 2017-07-06
EA037015B1 (ru) 2021-01-27
PL3397964T3 (pl) 2022-02-07

Similar Documents

Publication Publication Date Title
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
BR112017000671A2 (pt) moléculas com especificidade para cd79 e cd22
BR112018006360A2 (pt) anticorpos agonísticos que se ligam especificamente ao cd40 humano e métodos de uso
BR112017023872A2 (pt) anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
BR112017027990A2 (pt) modulação imune e tratamento de tumores sólidos com anticorpos que se ligam especificamente ao cd38
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
BR112016030908A2 (pt) moléculas com especificidade para cd45 e cd79
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112017006368A2 (pt) derivados de ácido borônico
BR112012016820A2 (pt) Metodos para tratamento de cancer de seio
BR112017008799A2 (pt) composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
BR112018000187A2 (pt) composto, composição, método, e, uso de um composto ou composição
BR112018002319A2 (pt) anticorpos anti-cd154 e métodos de uso dos mesmos
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
BR112017024163A2 (pt) compostos bicíclicos
BR112017009265A2 (pt) apilimode para uso no tratamento do câncer colorretal
BR112016018099A2 (pt) Compostos funcionalizados de benzopiranos e uso dos mesmos
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
BR112018013268A2 (pt) composições e métodos para detectar e tratar câncer gástrico
BR112019020414A2 (pt) composições e métodos para detectar e tratar câncer de próstata usando moléculas de ligação à progastrina
BR112019020412A2 (pt) composições e métodos para detectar câncer de pulmão
BR112017000303A2 (pt) métodos para o tratamento de hipotensão
BR112017006593A2 (pt) método para detectar câncer de ovário

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2651 DE 26-10-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.